Epstein-Barr Virus Infections
Neoplasms, Second Primary
Lymphoma, Large B-Cell, Diffuse
Antineoplastic Combined Chemotherapy Protocols
Combined Modality Therapy
Tumor Cells, Cultured
Herpesvirus 4, Human
Intensive investigation in management of Hodgkin's disease. (1/3116)Ninety-eight patients with clinically localised Hodgkin's disease underwent laparotomy and splenectomy to determine the extent of microscopic spread. In 68 patients the procedure was carried out for untreated disease apparently confined above the diaphragm. Abdominal disease cannot be confidently excluded on the basis of non-invasive investigation at presentation. Clinical assessment of splenic disease was unreliable unless gross splenomegaly was present. Pedal lymphography was accurate in assessing para-aortic and iliac disease but of no value in assessing other intra-abdominal lymph node involvement, including that of the mesenteric lymph node. Trephine bone marrow biopsy findings were normal in all patients before surgery, and only one patient was found to have diseased bone marrow by Stryker-saw biopsy at operation. Liver disease was identified at operation in nine patients, some of whom were asymptomatic with clinically undetectable splenic and nodal disease. Detailed clinical staging failed to detect disease in one-third of patients who underwent laparotomy. These studies show that if radiotherapy is to remain the treatment of choice for disease truly localised to lymph nodes a detailed staging procedure, including laparotomy and splenectomy, remains essential. The value of this potentially curative treatment is considerably diminished in the patient who has been inadequately staged. (+info)
Prednisone in MOPP chemotherapy for Hodgkin's disease. (2/3116)High remission rates have been produced by MOPP (mustine, vincristine, procarbazine, and prednisone) chemotherapy in patients with advanced Hodgkin's disease, but the prednisone component has caused adverse effects in patients who have undergone radiotherapy. The remission rates and length of remission were reviewed in 211 patients with Hodgkin's disease who received chemotherapy either with or without prednisone. In contrast to the findings of a British study, there were no significant differences in remission rates or length of remission between patients who had received prednisone and patients who had not. There were differences between the British prospective study and this retrospective one, but it is difficult to know what accounted for the substantial differences in the findings. (+info)
Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. (3/3116)PURPOSE: Recent studies have suggested that lymphocyte-predominant Hodgkin's disease (LPHD) is both clinically and pathologically distinct from other forms of Hodgkin's disease, including classical Hodgkin's disease (CHD). However, large-scale clinical studies were lacking. This multicenter, retrospective study investigated the clinical characteristics and course of LPHD patients and lymphocyte-rich classical Hodgkin's disease (LRCHD) patients classified according to morphologic and immunophenotypic criteria. MATERIALS AND METHODS: Clinical data and biopsy material of all available cases initially submitted as LPHD were collected from 17 European and American centers, stained, and reclassified by expert pathologists. RESULTS: The 426 assessable cases were reclassified as LPHD (51%), LRCHD (27%), CHD (5%), non-Hodgkin's lymphoma (3%), and reactive lesion (3%); 11% of cases were not assessable. Patients with LPHD and LRCHD were predominantly male, with early-stage disease and few risk factors. Patients with LRCHD were significantly older. Survival and failure-free survival rates with adequate therapy were similar for patients with LPHD and LRCHD, and were stage-dependent and not significantly better than stage-comparable results for CHD (German trial data). Twenty-seven percent of relapsing LPHD patients had multiple relapses, which is significantly more than the 5% of relapsing LRCHD patients who had multiple relapses. Lymphocyte-predominant Hodgkin's disease patients had significantly superior survival after relapse compared with LRCHD or CHD patients; however, this was partly due to the younger average age of LPHD patients. CONCLUSION: The two subgroups of LPHD and LRCHD bore a close clinical resemblance that was distinct from CHD; the course was similar to that of comparable nodular sclerosis and mixed cellularity patients. Thorough staging is necessary to detect advanced disease in LPHD and LRCHD patients. The question of how to treat such patients, either by reducing treatment intensity or following a "watch and wait" approach, remains unanswered. (+info)
Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. (4/3116)PURPOSE: To determine the treatment outcome and clinical factors that are of prognostic significance for children and adolescents with relapsed or refractory Hodgkin's disease (HD) who received treatment with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation (HSCT). PATIENTS AND METHODS: Fifty-three consecutive children and adolescents 21 years of age or younger with relapsed or refractory HD underwent HSCT. RESULTS: At day 100 after transplantation, 29 patients (55%) were in a complete remission or maintained a continuous complete response, six (11%) had a partial response, and 11 (21%) failed to respond or had progressive disease. The failure-free survival (FFS) at 5 years was 31%, and overall survival was 43%. Twenty-one patients died of progressive HD, and nine died secondary to transplantation-related complications, including two secondary leukemias. Prognostic factors important for FFS were normal pretransplantation lactate dehydrogenase levels (5-year FFS = 42%), compared with patients with elevated LDH levels (5-year FFS = 0%) (P < .001), and disease sensitivity at the time of HSCT with FFS in untreated relapse, sensitive disease, and resistant disease 44%, 35%, and 9%, respectively (P = .06). There was no statistically significant difference in FFS or overall survival between age subgroups that were analyzed (< 13, 13 to 18, 19 to 21) or in comparison with an adult cohort. CONCLUSION: HSCT is an effective treatment modality that can result in long-term cures and should be considered for children and adolescents with relapsed HD. (+info)
Reduced health-related quality of life among Hodgkin's disease survivors: a comparative study with general population norms. (5/3116)BACKGROUND: Late complications after curative treatment of Hodgkin's disease are of special relevance because most of the cured are young adults. The aims of the present study were: (1) to compare health-related quality of life (HRQOL) in Hodgkin's disease (HD) survivors with normative data from the general Norwegian population and (2) to examine the relations between disease/treatment characteristics and HRQOL in the HD survivors. PATIENTS AND METHODS: 459 HD survivors aged 19-74 years (mean 44.0, SD 11.8) treated at the Norwegian Radium Hospital 1971-1991 were approached in 1994 and compared to norms from 2214 subjects approached in 1996. The norms are representative of the general Norwegian population. HRQOL was assessed by the Short Form 36 (SF-36), which measures HRQOL in eight separate scales (0 = worst health state, 100 = best health state). RESULTS: The HD survivors had lower scores than the normal controls on all scales after adjustment for age, gender and educational levels. Statistically significant differences (P < 0.01) were found in general health (10.4), physical functioning (6.1), role limitations (physical, 9.3), physical functioning (3.6) and in vitality (4.7). Patients with disease stage IB-IIB had the lowest scores on all scales. The differences in relation to stage/substage reached statistical significance (P < 0.01) in physical functioning and in role limitations (physical). Time since diagnosis, types of primary treatment or having relapsed were not associated with statistically significant differences in HRQOL. CONCLUSION: Long-term HD survivors have poorer HRQOL, primarily in physical health, than the general Norwegian population. (+info)
Bone marrow scintigraphy using technetium-99m antigranulocyte antibody in malignant lymphomas. (6/3116)BACKGROUND: The purpose of this study was to elucidate the clinical reliability of immunoscintigraphy (IS) to detect infiltration of the bone marrow in patients with malignant lymphoma. PATIENTS AND METHODS: Whole body IS was performed in 103 patients with Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) using Tc-99m labelled anti-NCA-95 which allows visualization of the granulopoietic bone marrow. Of these, 52% were studied prior to any therapy. Findings were compared to posterior iliac crest biopsy as well as MRI and/or follow-up examination. Criteria of marrow infiltration were a positive biopsy, positive follow-up, or positive results of MRI. RESULTS: Comparison of IS and biospy revealed concordant findings in 69 and discordant findings in 34 of 103 patients. Of the 34 patients with discordant results, IS showed lesions suspicious of bone marrow infiltration in 29 patients despite normal biopsy findings. When follow-up and additional examinations were taken into consideration, 10 patients remained with probably false positive and five with false negative IS findings. IS proved to be highly sensitive and specific in patients with HD (100% and 84%, respectively) and high-grade NHL (93% and 84%, respectively). Moderate sensitivity (60%) was found in low-grade NHL. This was possibly due to false negative IS in three to five patients with chemotherapy in contrast to one of five false negative results in patients without chemotherapy. CONCLUSION: Bone marrow scintigraphy using antigranulocyte antibodies is highly sensitive in HD and high-grade NHL. Positive findings in IS subsequent to a negative biopsy should be followed by guided re-biopsy or MRI. (+info)
Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. (7/3116)PURPOSE: Hodgkin's disease patients who never achieve complete remission with conventional chemotherapy (i.e., those with primary induction failure) have a poor prognosis. Some subjects who receive high-dose therapy with autologous hematopoietic progenitor-cell infusion experience prolonged progression-free survival. PATIENTS AND METHODS: Detailed records from the Autologous Blood and Marrow Transplant Registry (ABMTR) on 122 Hodgkin's disease patients who failed to achieve complete remission after one or more conventional therapy regimens and subsequently received an autotransplant between 1989 and 1995 were reviewed. RESULTS: Median age was 27 years (range, 7 to 57 years). Median time from diagnosis to transplantation was 14 months (range, 5 to 38 months). Most patients received high-dose chemotherapy without radiation for pretransplantation conditioning (n = 107). The regimen most frequently used was cyclophosphamide, carmustine, and etoposide (n = 47). Fifteen patients received total-body irradiation (n = 15). The graft consisted of bone marrow (n = 86), blood stem cells (n = 25), or both (n = 11). The 100-day mortality was 12% (95% confidence interval, 7% to 19%). Sixty patients (50%) were considered to have achieved complete remission after autotransplantation; 37 of these had negative imaging studies, whereas scan abnormalities of unknown significance persisted in 23 patients. Twenty-seven patients (22%) had no response or progressive disease after transplantation. Probabilities of progression-free and overall survival at 3 years were 38% (95% confidence interval, 28% to 48%) and 50% (95% confidence interval, 39% to 60%), respectively. In multivariate analysis, "B" symptoms at diagnosis and poor performance score at transplantation were adverse prognostic factors for outcome. CONCLUSION: Autotransplants should be considered for patients with Hodgkin's disease who do not achieve complete remission with conventional therapy. (+info)
Stimulation of autologous blood lymphocytes by malignant lymphoma cells and homogenates. (8/3116)The blastogenic response to autologous blood lymphocytes to whole-cell suspensions and to homogenates obtained from malignant lymphoma tissue has been investigated. Spleens were obtained from patients in whom laparotomy was performed for staging of malignant lymphoma. Cell suspensions prepared from tumour nodules were treated with mitomycin C and allowed to react with separated autologous blood lymphocytes for 6 days. Lymphocyte stimulation was measured by liquid scintillation counting after exposure to 3H-TdR. Cultures were also prepared in which autologous lymphocytes were treated with spleen tumour homogenate. Control experiments used spleens from staging procedures in which no tumour deposits were present, and normal spleens removed incidentally during other operations. In the controls, the uptake of TdR was never more than twice that of unstimulated lymphocytes. Greater degrees of lymphocyte stimulation were seen in 6 out of 14 patients, using whole tumour cells, and in 7 out of 16 patients, using tumour homogenates. The results indicate an antigenic difference between tumour and host cells, and suggest that lymphocytes can react to a tumour-associated antigen. (+info)
Hodgkin Disease can spread to other parts of the body through the lymphatic system, and it can affect people of all ages, although it is most common in young adults and teenagers. The symptoms of Hodgkin Disease can vary depending on the stage of the disease, but they may include swollen lymph nodes, fever, night sweats, fatigue, weight loss, and itching.
There are several types of Hodgkin Disease, including:
* Classical Hodgkin Disease: This is the most common type of Hodgkin Disease and is characterized by the presence of Reed-Sternberg cells.
* Nodular Lymphocytic predominant Hodgkin Disease: This type of Hodgkin Disease is characterized by the presence of nodules in the lymph nodes.
* Mixed Cellularity Hodgkin Disease: This type of Hodgkin Disease is characterized by a mixture of Reed-Sternberg cells and other immune cells.
Hodgkin Disease is usually diagnosed with a biopsy, which involves removing a sample of tissue from the affected lymph node or other area and examining it under a microscope for cancer cells. Treatment for Hodgkin Disease typically involves chemotherapy, radiation therapy, or a combination of both. In some cases, bone marrow or stem cell transplantation may be necessary.
The prognosis for Hodgkin Disease is generally good, especially if the disease is detected and treated early. According to the American Cancer Society, the 5-year survival rate for people with Hodgkin Disease is about 85%. However, the disease can sometimes recur after treatment, and the long-term effects of radiation therapy and chemotherapy can include infertility, heart problems, and an increased risk of secondary cancers.
Hodgkin Disease is a rare form of cancer that affects the immune system. It is most commonly diagnosed in young adults and is usually treatable with chemotherapy or radiation therapy. However, the disease can sometimes recur after treatment, and the long-term effects of treatment can include infertility, heart problems, and an increased risk of secondary cancers.
Symptoms of EBV infection can vary widely, ranging from asymptomatic to severe, and may include:
* Sore throat
* Swollen lymph nodes in the neck and armpits
* Swollen liver or spleen
* Muscle weakness
In some cases, EBV can lead to more serious complications such as infectious mononucleosis (IM), also known as glandular fever, which can cause:
* Enlarged liver and spleen
* Splenomegaly (enlargement of the spleen)
* Hepatomegaly (enlargement of the liver)
* Thrombocytopenia (low platelet count)
* Anemia (low red blood cell count)
* Leukopenia (low white blood cell count)
EBV is also associated with an increased risk of developing certain types of cancer, including Burkitt lymphoma, Hodgkin lymphoma, and nasopharyngeal carcinoma.
There is no specific treatment for EBV infections, and most cases resolve on their own within a few weeks. Antiviral medications may be prescribed in severe cases or to prevent complications. Rest, hydration, and over-the-counter pain relief medication can help alleviate symptoms.
There are several types of lymphoma, including:
1. Hodgkin lymphoma: This is a type of lymphoma that originates in the white blood cells called Reed-Sternberg cells. It is characterized by the presence of giant cells with multiple nucleoli.
2. Non-Hodgkin lymphoma (NHL): This is a type of lymphoma that does not meet the criteria for Hodgkin lymphoma. There are many subtypes of NHL, each with its own unique characteristics and behaviors.
3. Cutaneous lymphoma: This type of lymphoma affects the skin and can take several forms, including cutaneous B-cell lymphoma and cutaneous T-cell lymphoma.
4. Primary central nervous system (CNS) lymphoma: This is a rare type of lymphoma that develops in the brain or spinal cord.
5. Post-transplantation lymphoproliferative disorder (PTLD): This is a type of lymphoma that develops in people who have undergone an organ transplant, often as a result of immunosuppressive therapy.
The symptoms of lymphoma can vary depending on the type and location of the cancer. Some common symptoms include:
* Swollen lymph nodes
* Weight loss
* Night sweats
Lymphoma is diagnosed through a combination of physical examination, imaging tests (such as CT scans or PET scans), and biopsies. Treatment options for lymphoma depend on the type and stage of the cancer, and may include chemotherapy, radiation therapy, immunotherapy, or stem cell transplantation.
Overall, lymphoma is a complex and diverse group of cancers that can affect people of all ages and backgrounds. While it can be challenging to diagnose and treat, advances in medical technology and research have improved the outlook for many patients with lymphoma.
Previous articleNeoplastic Cells
DLBCL is characterized by the rapid growth of malignant B cells in the lymph nodes, spleen, bone marrow, and other organs. These cells can also spread to other parts of the body through the bloodstream or lymphatic system. The disease is often aggressive and can progress quickly without treatment.
The symptoms of DLBCL vary depending on the location and extent of the disease, but they may include:
* Swollen lymph nodes in the neck, underarm, or groin
* Night sweats
* Weight loss
* Abdominal pain or discomfort
The diagnosis of DLBCL is based on a combination of physical examination findings, imaging studies (such as CT scans or PET scans), and biopsy results. Treatment typically involves a combination of chemotherapy, radiation therapy, and in some cases, immunotherapy or targeted therapy. The prognosis for DLBCL has improved significantly over the past few decades, with overall survival rates ranging from 60% to 80%, depending on the stage and other factors.
There are several subtypes of NHL, including:
1. B-cell lymphomas (such as diffuse large B-cell lymphoma and follicular lymphoma)
2. T-cell lymphomas (such as peripheral T-cell lymphoma and mycosis fungoides)
3. Natural killer cell lymphomas (such as nasal NK/T-cell lymphoma)
4. Histiocyte-rich B-cell lymphoma
5. Primary mediastinal B-cell lymphoma
6. Mantle cell lymphoma
7. Waldenström macroglobulinemia
8. Lymphoplasmacytoid lymphoma
9. Myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) related lymphoma
These subtypes can be further divided into other categories based on the specific characteristics of the cancer cells.
Symptoms of NHL can vary depending on the location and size of the tumor, but may include:
* Swollen lymph nodes in the neck, underarm, or groin
* Weight loss
* Night sweats
* Abdominal pain
* Swollen spleen
Treatment for NHL typically involves a combination of chemotherapy, radiation therapy, and in some cases, targeted therapy or immunotherapy. The specific treatment plan will depend on the subtype of NHL, the stage of the cancer, and other individual factors.
Overall, NHL is a complex and diverse group of cancers that require specialized care from a team of medical professionals, including hematologists, oncologists, radiation therapists, and other support staff. With advances in technology and treatment options, many people with NHL can achieve long-term remission or a cure.
Ann Arbor staging
Pieter Klazes Pel
Nodular lymphocyte predominant Hodgkin lymphoma
List of pathologists
John Millington Synge
Mark Fields (linebacker)
Joe C. Davis Jr.
Ian Gordon Lindsay
Prince Bernhard of Orange-Nassau, van Vollenhoven
John Frederick Wilkinson
Compensation scheme for radiation-linked diseases
Leukemia & Lymphoma Society
One Life to Live storylines (1990-1999)
Maynard v West Midlands Regional HA
Deaths in March 2017
Charles Taze Russell
List of Swarthmore College people
1934 in science
Primary effusion lymphoma
Mature T-cell lymphoma
Richard L. Wilson
Thoracic Hodgkin Disease (Lymphoma) Imaging: Practice Essentials, Radiography, Computed Tomography
Hodgkin Lymphoma | Hodgkin Disease | Lymphoma | MedlinePlus
Hodgkin Disease: Jacqueline's Story
Nodular Lymphocyte Predominant Hodgkin Lymphoma | Hodgkin's Disease
Hodgkin Lymphoma after Disseminated Mycobacterium genavense Infection, Germany - Volume 28, Number 7-July 2022 - Emerging...
Immunotherapy for Hodgkin's disease<...
FDA Approves Adcetris for Refractory Hodgkin's Disease and a Rare T-Cell Lymphoma - Medical Lessons
Lymphoma, Non-Hodgkin | Diseases and Disorders
Hodgkin's Disease (Lymphoma) - InsideSurgery Medical Information Blog
Expression of MicroRNA-155 in Patients with Non-Hodgkin Lymphoma, Coronavirus Disease 2019, or Both: A Cross-Sectional Study. ...
Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma - Full Text View -...
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with...
Hyperhidrosis Differential Diagnoses
Community Rallies to Light It Up Blue for Autism Awareness | URMC Newsroom
Acanthosis Nigricans: Background, Pathophysiology, Etiology
Etiology and management of therapy-related myeloid leukemia
Bone Involvement in Hodgkin's Lymphoma: Clinical Features and Outcome | Acta Haematologica | Karger Publishers
Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide...
Velban (vinblastine) dosing, indications, interactions, adverse effects, and more
Usnea Barbata - ABC Homeopathy
DailyMed - BLEOMYCIN injection
Predictors of risk of relapse in classic Hodgkin lymphoma | Journal of Clinical Pathology
NIOSHTIC-2 Search Results - Full View
SciELO - Brazil - Current treatment options for craniofacial hyperhidrosis Current treatment options for craniofacial...
When Cancer Was Conquerable
WHO EMRO | Pesticide exposure as a risk factor for lymphoproliferative disorders in adults | Volume 20, issue 6 | EMHJ volume...
- Hodgkin disease (lymphoma) is a cancer of the lymph system that is characterized by the presence of large, abnormal Reed-Sternberg cells in a background of lymphocytes, macrophages, fibroblasts, and granulocytes. (medscape.com)
- Classical Hodgkin lymphoma (HL) accounts for approximately 95% of all HL cases, with the other 5% being nodular lymphocyte-predominant HL (NLP-HL). (medscape.com)
- Hodgkin lymphoma has an incidence of about 3 new cases per 100,000 individuals per year, making it one of the most common lymphomas. (medscape.com)
- CT, MRI, PET/CT, and PET/MRI play a major role in the diagnosis, staging, and response to therapy of Hodgkin lymphoma. (medscape.com)
- What is Hodgkin lymphoma? (medlineplus.gov)
- Hodgkin lymphoma, also called Hodgkin disease, is a type of cancer that develops in the lymph system. (medlineplus.gov)
- Hodgkin lymphoma is one of the main types of lymphoma . (medlineplus.gov)
- The other is non-Hodgkin lymphoma. (medlineplus.gov)
- What causes Hodgkin lymphoma? (medlineplus.gov)
- The cause of Hodgkin lymphoma is unknown. (medlineplus.gov)
- Who is more likely to develop Hodgkin lymphoma? (medlineplus.gov)
- Hodgkin lymphoma is most common in early adulthood (age 20-39 years) and in late adulthood (age 65 years and older). (medlineplus.gov)
- The risk of adult Hodgkin lymphoma is slightly higher in males than in females. (medlineplus.gov)
- Having an infection with EBV as a young child or teenager increases your risk of Hodgkin lymphoma. (medlineplus.gov)
- A family history of Hodgkin lymphoma. (medlineplus.gov)
- Having a parent or sibling with Hodgkin lymphoma increases your risk of developing it. (medlineplus.gov)
- What are the symptoms of Hodgkin lymphoma? (medlineplus.gov)
- How is Hodgkin lymphoma diagnosed? (medlineplus.gov)
- What are the treatments for Hodgkin lymphoma? (medlineplus.gov)
- Hodgkin lymphoma can usually be cured if it is found and treated early. (medlineplus.gov)
- After seeing doctor after doctor, I was diagnosed with Hodgkin lymphoma stage 3. (bmtinfonet.org)
- My mom found a clinical trial at Memorial Sloan Kettering for patients with Hodgkin lymphoma. (bmtinfonet.org)
- Nodular lymphocyte predominant Hodgkin lymphoma is an uncommon form of Hodgkin's lymphoma . (knowcancer.com)
- Certain features of nodular lymphocyte predominant Hodgkin lymphoma distinguish it from other types of lymphoma. (knowcancer.com)
- Approximately 8,000 Americans are diagnosed with Hodgkin lymphoma each year and about 5-10% of those are nodular lymphocyte predominant Hodgkin lymphoma cases. (knowcancer.com)
- In approximately 3% of these cases the nodular lymphocyte predominant Hodgkin lymphoma goes beyond the lymph nodes and metastasizes into the bone marrow. (knowcancer.com)
- The main symptom of nodular lymphocyte predominant Hodgkin lymphoma is enlarged lymph nodes. (knowcancer.com)
- The cells of Nodular lymphocyte predominant Hodgkin lymphoma spread in an orderly fashion from one lymph node to another. (knowcancer.com)
- A combination of chemotherapy and radiotherapy are generally used to treat nodular lymphocyte predominant Hodgkin lymphoma. (knowcancer.com)
- Since nodular lymphocyte predominant Hodgkin lymphoma is often detected and diagnosed in the early stages prognosis is very good. (knowcancer.com)
- We report a case of disseminated M. genavense infection preceding Hodgkin lymphoma in a patient without obvious risk factors for this infection. (cdc.gov)
- Clinical manifestations and radiologic findings in the course of disease in a 23-year-old woman with disseminated M. genavense infection preceding Hodgkin lymphoma, Germany. (cdc.gov)
- Seattle Genetics disclosed that the annual cost for Adcetris, which the FDA approved late last week to combat Hodgkin's disease and another rare lymphoma, will cost $13,500 per dose. (medicallessons.net)
- Early clinical data suggest that patients who received Adcetris for Hodgkin lymphoma and systemic anaplastic lymphoma experienced a significant response to the therapy," said Richard Pazdur, M.D., in the late-Friday press release . (medicallessons.net)
- Nursing Central , nursing.unboundmedicine.com/nursingcentral/view/Diseases-and-Disorders/73653/all/Lymphoma__Non_Hodgkin. (unboundmedicine.com)
- Expression of MicroRNA-155 in Patients with Non-Hodgkin Lymphoma, Coronavirus Disease 2019, or Both: A Cross-Sectional Study. (bvsalud.org)
- Non-Hodgkin lymphoma (NHL) is the eleventh leading cause of cancer -related death in the world. (bvsalud.org)
- A Prospective Phase II Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients Aged 61 Years And Older, With Classical Hodgkin Lymphoma And Coexisting Medical Conditions. (clinicaltrials.gov)
- ABSTRACT In view of the widespread use of pesticides in Egypt and the increasing incidence of leukaemia and lymphoma we aimed to assess pesticide exposure and other selected variables as risk factors for lymphoproliferative disorders (leukaemia and non-Hodgkin lymphoma). (who.int)
- The risk was significant for cases of non-Hodgkin lymphoma but not chronic lymphocytic leukaemia. (who.int)
- They are broadly classified into Hodgkin lymphoma and non-Hodgkin lymphoma. (sun-sentinel.com)
- Specifically, these imaging exams have been validated for use only in Hodgkin lymphoma and in several forms of the most common types of non-Hodgkin lymphoma. (sun-sentinel.com)
- In cases of lymphoma where PET scans are worthwhile, a scan typically is conducted before treatment begins to identify disease stage. (sun-sentinel.com)
- For example, a patient with Hodgkin lymphoma may have a mass develop as part of the disease. (sun-sentinel.com)
- Velban is a prescription medication used to treat a variety of cancers including Hodgkin's disease, lymphoma, breast cancer, testicular cancer , and a certain type of uterine cancer . (rxwiki.com)
- Lymphosarcoma does not included Hodgkin's disease, and is therefore, also referred to as non-Hodgkin's lymphoma. (cdc.gov)
- non-Hodgkin lymphoma, other and unspecified types (C85. (who.int)
- en la variante de predominio linfocítico, nodular, se ven linfocitos e histiocitos. (bvsalud.org)
- A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. (bvsalud.org)
Centers for Diseas2
- I was among the 15 percent of patients with this disease for whom chemo, alone, didn't work. (bmtinfonet.org)
- Mycobacterium genavense infection, a rare nontuberculous mycobacteria infection, occurs in heavily immunocompromised patients (i.e., those with advanced HIV disease, genetic disorders, or acquired immunologic disorders and those undergoing immunosuppressive therapy). (cdc.gov)
- Mycobacterium genavense was first described in 1992 in HIV-positive patients with low CD4 counts and disseminated mycobacterial disease ( 1 ). (cdc.gov)
- EBV proteins present in the malignant Hodgkin Reed-Sternberg (HR-S) cells of about 40% of patients with Hodgkin's Disease (HD) provide targets for immunotherapy with virus-specific cytotoxic T lymphocytes (CTL). (houstonmethodist.org)
- Between 1972 and 1994, 121 adult patients with advanced Hodgkin's disease received MOPP (M) combination chemotherapy, MOPP alternating with ABVD (M-A) or MOPP and ABV hybrid (M/A). Radiation therapy was given to 1/3 of them. (haifa.ac.il)
- Today, 80% of patients with advanced Hodgkin's disease may be cured, with low rate of long-term toxicity. (haifa.ac.il)
- In case of progressive disease, according to Lugano Classification (Cheson et al.2014, PET-CT scan based response) patients will be considered in treatment failure. (clinicaltrials.gov)
- In case of progressive disease , patients will be considered in treatment failure. (clinicaltrials.gov)
- Patients with t-AML should be enrolled on front-line chemotherapy trials, appropriate for de novo AML patients with similar disease characteristics. (nih.gov)
- Patients whose disease goes into remission after three rounds of chemotherapy are most likely to stay in remission the longest, and that provides valuable information to guide additional treatment. (sun-sentinel.com)
- The license for adult use was granted under FDA's accelerated approval pathway, which allows the agency to approve products for serious or life-threatening diseases on the basis of early evidence of a product's effectiveness that is reasonably likely to predict clinical benefit. (cdc.gov)
- Positron emission tomography (PET) scanning with fluorodeoxyglucose (FDG) is most useful for detecting disease relapse. (medscape.com)
- Up to winter 2021-2022, the death toll caused by the coronavirus disease 2019 (COVID-19) has exceeded 5.6 million worldwide. (bvsalud.org)
- I thought cancer was an older person's disease. (bmtinfonet.org)
- FDG/PET and MRI can identify involvement of bone marrow, and imaging can confirm poor prognostic indicators such as large mediastinal adenopathy, stage IV disease, systemic symptoms, and pleural effusion and pericardial effusion. (medscape.com)
- Bone scanning is useful for evaluating bone involvement in Hodgkin disease. (medscape.com)
- The last step before my bone marrow transplant would be radiation to get rid of the remaining disease. (bmtinfonet.org)
- Clinically, CTL produced resolution of B symptoms and mixed tumor responses including one complete remission of residual disease remaining after autologous bone marrow transplant. (houstonmethodist.org)
- Clinicians generally classify the disease based on whether it predominantly affects the skin, in which case it tends to be indolent, or if it affects internal organs like the bone marrow, liver and brain, in which case it tends to be aggressive and be unresponsive to standard chemo regimens like CHOP . (medicallessons.net)
- The reason to perform an interim scan after three rounds of chemotherapy is to find out if the disease has gone into remission. (sun-sentinel.com)
- He or she can undergo chemotherapy that puts the disease into remission, but a portion of the mass that's not cancerous might remain behind. (sun-sentinel.com)
- ORRHES) requested that the Agency for Toxic Substances and Disease Registry (ATSDR) and the Tennessee Cancer Registry (TCR) of the Tennessee Department of Health assess the incidence of cancer in this area. (cdc.gov)
- However, Hodgkin tumors use multiple strategies to avoid CTL, including down-regulation of immunodominant EBV antigens, and secretion of cytokines and chemokines such as TGF-β, that inhibit the activation of CTL and professional antigen-presenting cells (APC). (houstonmethodist.org)
- Future clinical studies will test the efficacy of CTL with improved antigen-specificity and resistance to Hodgkin immune evasion strategies. (houstonmethodist.org)
- It helps protect your body from infection and disease. (medlineplus.gov)
- In some cases the treatment can cause more harm than the disease itself. (knowcancer.com)
- For this nontuberculous mycobacteria (NTM) disease, diagnostic criteria are ill defined and no treatment guidelines are established. (cdc.gov)
- Some of these antineoplastic agents are also being used for other purposes such as the treatment of nonmalignant diseases. (cdc.gov)
- If the disease is not in remission, at that point, the treatment plan likely needs to change to combat the disease more effectively. (sun-sentinel.com)
- The incidence of invasive disease ranges from 3.8 per 100,000 among persons aged 18-34 years to 36.4 per 100,000 among those aged ≥65 years ( 4 ). (cdc.gov)
- 51 disease terms (MeSH) has been reported with MYB gene. (cdc.gov)
- effective than conventional drugs in targeting disease. (who.int)
- Gallium-67 ( 67 Ga) scans obtained at baseline, during therapy, and in the posttreatment period can help differente active Hodgkin disease from nonactive Hodgkin disease. (medscape.com)
- This will include checking for signs of disease, such as lumps or anything else that seems unusual. (medlineplus.gov)
- Mediastinal adenopathy is the most common presentation, and direct extension of the disease can be detected on chest radiographs. (medscape.com)
- certain localized infections - see body system-related chapters infectious and parasitic diseases complicating pregnancy, childbirth and the puerperium [except obstetrical tetanus] (O98. (who.int)
- Since then, we have spent nearly $200 billion in federal money on research to defeat the disease. (reason.com)
- The Agency for Toxic Substances and Disease Registry (ATSDR), a public health agency of the U.S. Department of Health and Human Services, has issued the final version of its public health assessment on the Lawrence Livermore National Laboratory Main Site (LLNL), Livermore, Calif. The lab is operated by the University of California for the U.S. Department of Energy. (cdc.gov)
- Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry. (cdc.gov)
- CDHS prepared the report under a cooperative agreement with the federal Agency for Toxic Substances and Disease Registry (ATSDR), part of the U.S. Department of Health and Human Services. (cdc.gov)
- The Agency for Toxic Substances and Disease Registry (ATSDR) will hold a community meeting Aug.11 to discuss its findings from the public health assessment conducted on the Lawrence Livermore National Lab site (LLNL). (cdc.gov)